Please make sure that HealthWell currently has a fund for your diagnosis/indication and that your medication is covered under that fund by visiting our Diseases and Medications listing. If we do not have a fund that currently covers your diagnosis, please check back as we frequently open and reopen programs as funding becomes available. The Foundation is able to help patients receiving treatment for indications for which we currently have an open fund. We can only assist with medications that have been prescribed to treat the disease/covered diagnosis. You will be asked to provide the Foundation with the patient’s diagnosis, which must be verified by a physician, nurse practitioner, or physician assistant’s signature. The patient must receive treatment in the United States.
Metabolic Dysfunction-Associated Steatohepatitis
Status
ClosedThis fund is temporarily closed to new patients due to lack of sufficient funding. Please continue to visit our Disease Funds page often, as replenished funds reopen as quickly as possible. If you currently have a grant with HealthWell, your grant will remain active for the entire 12 month grant cycle or until you have exhausted your allocated grant amount, whichever comes first. You can continue to use your pharmacy card or submit requests for reimbursements during your designated grant cycle.
Fund Type
CopayPremium (Medicare Part B only)
Maximum Award Level
Pharmacy Card Fund
YesMinimum CopayReimbursement Amount
We encourage you to please use your HealthWell pharmacy card for any applicable charges as possible.
Minimum Premium
Reimbursement Amount
Household Income Limit
500% of the Federal Poverty Level(adjusted for household size and high
cost of living areas)
Treatments Covered
- Actos
- Imaging (ct, Mri, Ultrasound)*
- Lab Work (related To The Liver)*
- Liver Biopsy*
- Ozempic 0.25 Mg Or 0.5 Mg Doses
- Ozempic 1 Mg Doses
- Ozempic 2 Mg Doses
- Physician Visit (hepatologist)*
- Pioglitazone
- Pioglitazone Hcl
- Pioglitizone Hydrochloride
- Reltone
- Resmetirom
- Rezdiffra
- Rybelsus
- Semaglutide
- Transportation-bus
- Transportation-car Mileage
- Transportation-taxi
- Transportation-train
- Urso 250
- Urso Forte
- Ursodiol
- Ursodiol Avpak
- Wegovy
*These products are not billable through HealthWell’s pharmacy card. Please submit requests for reimbursement through our paper claim process.
Fund Definition
Assistance with premium, copayment, coinsurance and deductibles related to (a) prescription drugs and (b) physician visits and diagnostic testing to monitor treatment. Assistance is also offered for transportation costs for treatment and monitoring.
Grant Utilization
HealthWell estimates that patients use an average of $3,250 during their 12-month grant period for this disease area.
Do I Qualify?
HealthWell bases eligibility on an individual’s medical, financial and insurance situation. To qualify for HealthWell’s assistance, applicants must meet the following eligibility requirements:
-
-
To qualify for copayment assistance from HealthWell, you must have some form of health insurance (private insurance, Medicare, Medicaid, TriCare, etc.) that covers part of the cost of your treatment. Please note that in order to qualify for premium assistance through this fund, you must have Medicare Part B. The Foundation will refer patients without prescription insurance to other programs, such as manufacturer patient assistance programs.
-
HealthWell assists individuals with incomes up to 300-500% of the Federal Poverty Level. The Foundation also considers the number in a household and cost of living in a particular city or state. If you believe you qualify for assistance, you may begin the application process here.
-
If you are receiving treatment in the U.S. and have met the eligibility criteria as listed, you are ready to apply! Please note that you will be asked to provide a Social Security Number in order to create a grant. This information is gathered to eliminate duplicate applications and is kept secure and confidential.
About Metabolic Dysfunction-Associated Steatohepatitis
MASH, previously referred to as nonalcoholic steatohepatitis (NASH), is a severe form of nonalcoholic fatty liver disease that causes the liver to swell and become damaged. Progressive fibrosis (scarring), leading to cirrhosis of the liver, is the primary risk and occurs in 5 to 12 percent of people living with MASH. MASH is also associated with an increased risk of cardiovascular disease and type 2 diabetes. A few common risk factors for MASH include high cholesterol, high blood pressure, overweight, high blood sugar, and metabolic syndrome. The presence of MASH with other risk factors such as older age and diabetes may increase the risk of progression to end-stage liver disease.
Additional Educational Resources
You may also visit our Resource List to view other copayment organizations that may provide assistance.
